Showing results (1-10 of 103) with videos related to
Sort By:
Pageof 11
Pharmacoeconomics|May 27, 2020
Financing Drug Innovation in the US: Current Framework and Emerging ChallengesDavid Cutler, Noam Kirson, Genia LongThe American Journal of Managed Care|December 21, 2017
Insurance switching and mismatch between the costs and benefits of new technologiesDavid Cutler, Michael Ciarametaro, Genia Long, et al.Health Affairs (Project Hope)|November 10, 2011
Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman ActHenry G Grabowski, Margaret Kyle, Richard Mortimer, et al.Journal of Medical Economics|June 14, 2019
Federal government-interest patent disclosures for recent top-selling drugsGenia LongJournal of Medical Economics|March 25, 2026
Trends in industry-sponsored clinical trial activity since passage of the Inflation Reduction ActGenia LongJournal of Medical Economics|February 29, 2024
Post-approval indications and clinical trials for cardiovascular drugs: some implications of the US Inflation Reduction ActHenry Grabowski, Genia LongExpert Opinion on Therapeutic Patents|May 1, 2015
The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticalsIain Cockburn, Genia LongJournal of Medical Economics|December 11, 2013
Recent trends in brand-name and generic drug competitionHenry Grabowski, Genia Long, Richard MortimerHealth Affairs (Project Hope)|September 13, 2006
The market for follow-on biologics: how will it evolve?Henry Grabowski, Iain Cockburn, Genia LongJournal of Medical Economics|September 16, 2014
Evolving provider payment models and patient access to innovative medical technologyGenia Long, Richard Mortimer, Geoffrey SanzenbacherPageof 11